An NDA is the application through which FDA approves a new drug for marketing, under section 505 of the FD&C Act and 21 CFR Part 314. The temptation is to treat it as the IND's bigger sibling — the same exercise with a longer form. The mechanics are opposite. An IND goes into effect because 30 days passed; an NDA confers nothing until the agency affirmatively acts. And the “PDUFA date” that whole companies plan around is not a deadline the statute enforces. It is a goal the agency set for itself.

Why the framing matters

If you believe the PDUFA date is a deadline, you build the launch on it: manufacturing scale-up timed to it, commercial hiring timed to it, investor communications anchored to it. Every one of those plans inherits a risk the regulation never priced. The date obliges FDA to nothing — it is a goal the agency commits to under the Prescription Drug User Fee Act reauthorizations, met in most cases, extended by three months if you submit a major amendment late in the cycle, and consequence-free when missed.

The second inherited error is worse: assuming the action on that date will be an approval. The review cycle ends in one of two letters. One approves the drug. The other — the complete response letter — tells you the application cannot be approved in its present form and lists what is missing. Teams that treated the goal date as a launch date discover that the resubmission which answers a CRL starts a new review clock entirely. This is the same lesson the 510(k)'s 90-day MDUFA goal teaches on the device side: a performance goal is someone else's promise about throughput, not your regulatory status.

The terms, precisely

NDA (New Drug Application)
The application under section 505(b) of the FD&C Act for approval to market a new drug in the United States. Its regulations live in 21 CFR Part 314 — contents at 314.50, the filing decision at 314.101, the possible actions at 314.100–314.110.
Filing
FDA's threshold decision, within 60 days of submission, that the application is sufficiently complete to permit a substantive review. An application that is not — missing studies, unresolvable format problems — is refused for filing. Submission is not filing, and the review goals run from filing for new molecular entities.
PDUFA goal date
The date by which FDA aims to act on the application under its user-fee performance goals: for a new molecular entity, ten months from the 60-day filing date on standard review, six months on priority review. A goal, publicly committed to and usually met — but not a right the applicant holds.
Complete response letter (CRL)
The action that ends a review cycle without approval. It describes the deficiencies — clinical, manufacturing, labeling — that stand between the application and approval. Under 21 CFR 314.110 the applicant resubmits, withdraws, or requests a hearing; a resubmission opens a new cycle with a two- or six-month goal.

What the file actually argues

The case, per 21 CFR 314.50
  1. Effectiveness — substantial evidence from adequate and well-controlled investigations that the drug does what the labeling says, the standard section 505(d) sets.
  2. Safety — full reports showing the drug is safe for use under the conditions in the proposed labeling, benefit weighed against risk for that population.
  3. Quality — the chemistry, manufacturing, and controls section: proof you can make the same drug, at scale, batch after batch, in facilities that will pass a pre-approval inspection.
  4. Labeling — the proposed prescribing information, which is what FDA actually approves. The drug reaches the market as its label, not as its data.

Notice the shape: unlike a 510(k), there is no predicate and no comparison. The evidence carries the whole application on its own merits — which is why the NDA's centre of gravity is the two adequate and well-controlled trials, and why so many complete response letters turn not on efficacy at all but on the manufacturing leg. A drug that works, made in a facility that failed inspection, is not an approvable application.

The clock, honestly

The honest timeline has more segments than “submit, then PDUFA date.” Sixty days to the filing decision, where a refuse-to-file sends the application back before review begins. Then the goal period — ten months from filing for a standard-review new molecular entity, six for priority — during which the agency conducts its review, may convene an advisory committee, inspects facilities, and negotiates labeling. A major amendment — a new study report, a significant reanalysis — can extend the goal by three months. And the cycle ends in an action: approval, or a CRL whose answer starts a fresh clock of two months (Class 1 resubmission) or six (Class 2).

So the honest project plan carries an approval window, not an approval date; it holds the launch spend behind the action letter, not the goal date; and it budgets one full CRL cycle in the downside case, because multi-cycle approvals are common enough that pretending otherwise is not optimism but planning error.

Where NDA planning goes wrong

Building the launch on the PDUFA date

The goal date binds nobody. Committing manufacturing, commercial teams, and market expectations to it converts a performance goal you do not control into a deadline you must explain. Plan the spend against the action letter — the date is when you will probably hear, not what you will hear.

Treating submission as filing

The 60-day filing review is a real gate, and a refuse-to-file is not a technicality — it says the application is not reviewable as submitted. Teams that announce “we submitted” as if the clock were running have, at that point, no clock at all.

Reading a complete response letter as a negotiation

A CRL is the end of a review cycle, not a comment round within one. Every deficiency it lists must be answered in a resubmission that FDA reviews on a new clock. The cheapest CRL is the one you prevent — which is what the pre-submission meetings, the inspection readiness, and the labeling groundwork were for.

Frequently asked questions

What happens if FDA misses the PDUFA goal date?

Nothing automatic. The goal date is a performance commitment under the user-fee program, not a statutory deadline — the review simply continues, and the agency meets the goal in the large majority of cases. No approval, no penalty, and no market access follows from the date passing.

Is a complete response letter a rejection?

FDA does not issue “rejections.” A complete response letter states that the review cycle is complete and the application cannot be approved in its present form, and lists the deficiencies. Resubmission starts a new review clock — two months for a Class 1 resubmission, six for Class 2 under 21 CFR 314.110.

What is the difference between an NDA and a BLA?

An NDA seeks approval of a drug under section 505 of the FD&C Act; a BLA seeks licensure of a biologic under section 351 of the PHS Act. The review architecture and PDUFA goals are the same in practice, but the statutes, the approval standards as written, and often the reviewing center differ.

Sources & further reading

  1. 21 CFR Part 314 — Applications for FDA Approval to Market a New Drug ecfr.gov
  2. FDA — New Drug Application (NDA): overview and contents fda.gov
  3. FDA — Prescription Drug User Fee Amendments: performance goals and commitments fda.gov

This lesson is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal or regulatory advice.